Search Result
Results for "
Tris(2-carboxyethyl)phosphine-biotin
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P11118A
-
|
CAPture peptide, biotin-CCDC61 (334-366) TFA
|
Biochemical Assay Reagents
|
Others
|
|
Biotinylated CCDC61 peptide (CAPture peptide, biotin-CCDC61 (334-366)) TFA is a biotinylated peptide derived from the centrosomal protein CCDC61. Biotinylated CCDC61 peptide TFA specifically isolates intact centrosomes .
|
-
-
- HY-P10620
-
|
|
Bacterial
|
Others
|
|
GGGYK-Biotin is a substrate peptide designed to study the substrate specificity of Sortase A. GGGYK-Biotin can be used to develop Sortase A variants with different substrate specificities .
|
-
-
- HY-P2510
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Parathyroid Hormone (1-34), human, biotinylated is a probe for the parathyroid hormone receptor, can be used for analyzing the interaction between parathyroid hormone and parathyroid hormone receptors in living cells and for purifying hormone-receptor complexes with affinity columns [2].
|
-
-
- HY-158738
-
|
Tris(2-carboxyethyl)phosphine-biotin
|
Fluorescent Dye
|
Others
|
|
TCEP-biotin is biotinylated TCEP (HY-W011500). TCEP-biotin is also a probe for histone lysine crotonylation .
|
-
-
- HY-P3844
-
-
-
- HY-P2551
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .
|
-
-
- HY-P2549
-
-
-
- HY-P11118
-
|
CAPture peptide, biotin-CCDC61 (334-366)
|
Biochemical Assay Reagents
|
Others
|
|
Biotinylated CCDC61 peptide (CAPture peptide, biotin-CCDC61 (334-366)) is a biotinylated peptide derived from the centrosomal protein CCDC61. Biotinylated CCDC61 peptide specifically isolates intact centrosomes .
|
-
-
- HY-P2504
-
|
|
Syk
|
Others
|
|
Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.
|
-
-
- HY-P3576
-
-
-
- HY-P3576A
-
-
-
- HY-P10569
-
|
|
EGFR
|
Cancer
|
|
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a Km value of 60 μm for Her2/neu kinase domain .
|
-
-
- HY-P2546
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
Biotin-Substance P is the biotin tagged Substance P. Substance P (Neurokinin P) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R) .
|
-
-
- HY-13443F
-
|
|
GCGR
|
Others
|
|
Exendin 4, biotin labeled is a biotin labeled Exendin 4 (HY-13443). Exendin 4 is a long-acting GLP-1 receptor agonist .
|
-
-
- HY-P10886
-
-
-
- HY-P5351A
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Hyaluronan-binding peptide, biotin labeled TFA is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.) .
|
-
-
- HY-P10566
-
|
|
BCL6
|
Cancer
|
|
BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .
|
-
-
- HY-P10828
-
|
|
Virus Protease
|
Infection
Inflammation/Immunology
|
|
MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection .
|
-
-
- HY-P10372
-
|
|
Src
|
Cancer
|
|
pFYN peptide is a biotin-labled phosphorylated peptide substrate derived from FYN (a Src family kinase) .
|
-
-
- HY-P2491
-
|
|
Fluorescent Dye
|
Cardiovascular Disease
Endocrinology
|
|
Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research [2].
|
-
-
- HY-P2136F
-
|
|
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Biotin-COG1410 TFA is a biotin labled COG1410 (HY-P2136). COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease [2].
|
-
-
- HY-P11307
-
|
|
Proteasome
|
Others
|
|
Biotin-epoxomicin is a biotin labeled Epoxomicin (HY-13821). Biotin-epoxomicin is a high affinity probe targeting Proteasome. Biotin-epoxomicin covalently binds to multiple proteasome catalytic subunits (such as LMP7, Z and MECL1) .
|
-
-
- HY-P11306
-
|
|
Proteasome
|
Others
|
|
Biotin-(Oaa)3-epoxomicin (Compound 13) is a biotinylated active form of Epoxomicin (HY-13821). Biotin-(Oaa)3-epoxomicin is a high affinity probe targeting Proteasome. Biotin-(Oaa)3-epoxomicin covalently binds to multiple proteasome catalytic subunits (such as LMP7, Z and MECL1) .
|
-
-
- HY-P3066
-
|
d(CH2)5Tyr(Et)VAVP
|
Vasopressin Receptor
|
Metabolic Disease
|
|
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
|
-
-
- HY-114118S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
|
-
-
- HY-114118S
-
|
|
Isotope-Labeled Compounds
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-158738
-
|
Tris(2-carboxyethyl)phosphine-biotin
|
Dyes
|
|
TCEP-biotin is biotinylated TCEP (HY-W011500). TCEP-biotin is also a probe for histone lysine crotonylation .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P11118A
-
|
CAPture peptide, biotin-CCDC61 (334-366) TFA
|
Biochemical Assay Reagents
|
Others
|
|
Biotinylated CCDC61 peptide (CAPture peptide, biotin-CCDC61 (334-366)) TFA is a biotinylated peptide derived from the centrosomal protein CCDC61. Biotinylated CCDC61 peptide TFA specifically isolates intact centrosomes .
|
-
- HY-P10620
-
|
|
Bacterial
|
Others
|
|
GGGYK-Biotin is a substrate peptide designed to study the substrate specificity of Sortase A. GGGYK-Biotin can be used to develop Sortase A variants with different substrate specificities .
|
-
- HY-P2510
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Parathyroid Hormone (1-34), human, biotinylated is a probe for the parathyroid hormone receptor, can be used for analyzing the interaction between parathyroid hormone and parathyroid hormone receptors in living cells and for purifying hormone-receptor complexes with affinity columns [2].
|
-
- HY-P3576A
-
-
- HY-P3844
-
-
- HY-P2551
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .
|
-
- HY-P2549
-
-
- HY-P11118
-
|
CAPture peptide, biotin-CCDC61 (334-366)
|
Biochemical Assay Reagents
|
Others
|
|
Biotinylated CCDC61 peptide (CAPture peptide, biotin-CCDC61 (334-366)) is a biotinylated peptide derived from the centrosomal protein CCDC61. Biotinylated CCDC61 peptide specifically isolates intact centrosomes .
|
-
- HY-P2504
-
|
|
Syk
|
Others
|
|
Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.
|
-
- HY-P3576
-
-
- HY-P10569
-
|
|
EGFR
|
Cancer
|
|
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a Km value of 60 μm for Her2/neu kinase domain .
|
-
- HY-P10244F
-
|
|
Peptides
|
Infection
|
|
Biotin-YVAD-FMK is an inhibitor for vacuolar processing enzyme (VPE), with a 64% inhibition at 5 μM. Biotin-YVAD-FMK is an irreversible substrate for caspase 1 [2].
|
-
- HY-P2546
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
Biotin-Substance P is the biotin tagged Substance P. Substance P (Neurokinin P) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R) .
|
-
- HY-13443F
-
|
|
GCGR
|
Others
|
|
Exendin 4, biotin labeled is a biotin labeled Exendin 4 (HY-13443). Exendin 4 is a long-acting GLP-1 receptor agonist .
|
-
- HY-P10886
-
-
- HY-P4078
-
|
|
Peptides
|
Others
|
|
(Arg)9 biotin labeled is a cell-permeable peptide. (Arg)9 biotin labeled can be used for drug delivery. (Arg)9 biotin labeled can traverse the plasma membrane of eukaryotic cells .
|
-
- HY-P5351
-
|
|
Peptides
|
Others
|
|
Hyaluronan-binding peptide, biotin labeled is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.)
|
-
- HY-P5351A
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Hyaluronan-binding peptide, biotin labeled TFA is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.) .
|
-
- HY-P10566
-
|
|
BCL6
|
Cancer
|
|
BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .
|
-
- HY-P10828
-
|
|
Virus Protease
|
Infection
Inflammation/Immunology
|
|
MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection .
|
-
- HY-P10372
-
|
|
Src
|
Cancer
|
|
pFYN peptide is a biotin-labled phosphorylated peptide substrate derived from FYN (a Src family kinase) .
|
-
- HY-P2491
-
|
|
Fluorescent Dye
|
Cardiovascular Disease
Endocrinology
|
|
Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research [2].
|
-
- HY-P4756
-
|
|
Peptides
|
Others
|
|
N-(2-Carbamoyl-ethyl)-Val-Leu-anilide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P2136F
-
|
|
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Biotin-COG1410 TFA is a biotin labled COG1410 (HY-P2136). COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease [2].
|
-
- HY-P11307
-
|
|
Proteasome
|
Others
|
|
Biotin-epoxomicin is a biotin labeled Epoxomicin (HY-13821). Biotin-epoxomicin is a high affinity probe targeting Proteasome. Biotin-epoxomicin covalently binds to multiple proteasome catalytic subunits (such as LMP7, Z and MECL1) .
|
-
- HY-P11306
-
|
|
Proteasome
|
Others
|
|
Biotin-(Oaa)3-epoxomicin (Compound 13) is a biotinylated active form of Epoxomicin (HY-13821). Biotin-(Oaa)3-epoxomicin is a high affinity probe targeting Proteasome. Biotin-(Oaa)3-epoxomicin covalently binds to multiple proteasome catalytic subunits (such as LMP7, Z and MECL1) .
|
-
- HY-P3066
-
|
d(CH2)5Tyr(Et)VAVP
|
Vasopressin Receptor
|
Metabolic Disease
|
|
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
|
-
- HY-114118S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
|
-
- HY-114118S
-
|
|
Isotope-Labeled Compounds
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-114118S1
-
|
|
|
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
|
-
-
- HY-114118S
-
|
|
|
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: